To test whether antibodies against β-amyloid are effective in slowing progression of Alzheimer's disease, we assessed cognitive functions in 30 patients who received a prime and a booster immunization of aggregated Aβ42 over a 1 year period in a placebo-controlled, randomized trial. Twenty patients generated antibodies against β-amyloid, as determined by tissue amyloid plaque immunoreactivity assay. Patients who generated such antibodies showed significantly slower rates of decline of cognitive functions and activities of daily living, as indicated by the Mini Mental State Examination, the Disability Assessment for Dementia, and the Visual Paired Associates Test of delayed recall from the Wechsler Memory Scale, as compared to patients without such antibodies. These beneficial clinical effects were also present in two of three patients who had experienced transient episodes of immunization-related aseptic meningoencephalitis. Our results establish that antibodies against β-amyloid plaques can slow cognitive decline in patients with Alzheimer's disease.

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease